Matthew Sherwood, MD
Interventional Cardiology · Falls Church, VANPI 1245356435
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 80.8% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $66,155, more than ten times the $3,026 reported in 2019. Among interventional cardiology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 378 payments — averaging $510.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$156K
- Boston Scientific$21K
- Abbott$10K
- Edwards Lifesciences$2K
- Philips North America LLC$1K
- Terumo Medical Corporation$700
- plus $2K from 11 others
Across 123 payments — averaging $2643.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$221K
- Medtronic$61K
- Abbott$29K
- Daiichi Sankyo Inc.$15K
- Abiomed$142
What the payments were for
- Consulting fees$34,77518%
- Speaking & faculty fees$102,87553%
- Travel & lodging$38,81020%
- Food & beverage$16,3348%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 219 | $155,741 |
| Boston Scientific | 38 | $20,533 |
| Abbott | 52 | $10,404 |
| Edwards Lifesciences | 15 | $1,982 |
| Philips North America LLC | 9 | $1,415 |
| Terumo Medical Corporation | 1 | $700 |
| Recor Medical Inc | 3 | $545 |
| Shockwave Medical, Inc | 4 | $301 |
| Cardiovascular Systems Inc. | 20 | $299 |
| E.r. Squibb & Sons, L.L.C. | 4 | $279 |
| Abiomed | 6 | $252 |
| Novartis | 1 | $126 |
| Pfizer | 1 | $114 |
| Johnson & Johnson | 2 | $32 |
| Stryker | 1 | $30 |
| Amgen | 1 | $24 |
| Livanova USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$146,856
- WATCHMAN FLX$7,520
- MitraClip$6,872
- Watchman$6,436
- WATCHMAN Access System$6,058
- CoreValve Evolut$3,526
- Resolute$1,212
- IGT Devices Und$1,055
- EVOQUE$601
- Paradise Ultrasound Renal Denervation System$500
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$253
- SAPIEN 3 Ultra RESILIA$185
- PASCAL$183
- SYMPLICITY G3$169
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$150
- Impella$147
- Dragonfly OCT$147
- Xience V coronary stent system$146
- MitraClip System$146
- LEQVIO$126
How this compares
$192,794 in reported general payments places this provider in the 95th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 37 | $46,947 |
| Metoprolol Succinate | 74 | $1,643 |
| Rosuvastatin Calcium | 81 | $1,572 |
| Atorvastatin Calcium | 112 | $1,446 |
| Ezetimibe | 36 | $1,018 |
| Valsartan | 17 | $756 |
| Carvedilol | 46 | $625 |
| Losartan Potassium | 55 | $394 |
| Lisinopril | 48 | $352 |
| Amlodipine Besylate | 45 | $301 |
| ClopidogrelClopidogrel Bisulfate | 18 | $299 |
| Spironolactone | 16 | $207 |
| Ramipril | 11 | $144 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 11 | $130 |
| FenofibrateFenofibrate Nanocrystallized | 13 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $114 | $46,94737 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Falls Church
- Noah JonesFalls Church$238K
- Wayne BatchelorFalls Church$196K
- Lindsey CiliaFalls Church$50K
- Nadim GelooFalls Church$41K
- Hazim El-HaddadFalls Church$39K
- Deepak TalrejaVirginia Beach$1.5M
- Rajiv TayalFredericksburg$984K
- Gansevoort DunningtonRichmond$440K
- Matthew SummersNorfolk$308K
- Michael GenVirginia Beach$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.